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Abstract 
Human embryonic stem cells (hESC) are harvested from the inner cell mass of the pre-implantation embryo and 
possess several unique characteristics. First, they are self-renewing, meaning they can grow indefinitely in an 
appropriate culture environment and secondly, they are pluripotent, which means they have the potential to 
become nearly every cell of the human body. Consequently, hESC offer a unique insight into basic human 
development in vitro, allow better understanding of the genetic and molecular controls of these processes, and 
are of pharmaceutical interest to test or develop new drugs. The most exciting and high-profile potential 
application of hESC research is the possibility that such cells can be used for regenerative medicine. Still, several 
obstacles have to be overcome before clinical applications can be considered: (i) xeno-free derivation and culture 
of hESC is necessary; (ii) hESC should be safe after transplantation and (iii) their identity and behaviour should 
be well-known. 
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 In 1998, Thomson and colleagues 
established the first human embryonic stem 
cells (hESC) from the inner cell mass of a 
human blastocyst stage embryo (1). The 
unique ability of hESC to proliferate 
indefinitely in culture and to differentiate 
into all cell types from the three germ 
layers (ecto-, endo- and mesoderm) created 
an explosion of interest and the emergence 
of a rapidly advancing field. Hence, hESC 
have become an indispensible tool across a 
wide range of scientific disciplines and 
hold great promise for treating many 
human diseases. From a basic science 
perspective, the study of how hESC 
differentiate into more specialized cells 
and tissues provides novel insight into 
human developmental biology. The use of 
hESC derived from embryos with genetic 
disorders provides in vitro models to study 
the pathology of diseases in clinically 
relevant cell types. Both normal and 
disease-model hESC have also been 
utilized in pharmaceutical research, using 
targeted cell types for in vitro drug and 
toxicology testing and drug development 
(2, 3). The most intriguing and potentially 
beneficial applications of hESC, however, 
are situated in the field of regenerative 
medicine (3). A large proportion of human 
diseases are the result of cellular 
dysfunction, degeneration, or damage. It is 
hypothesized that differentiated hESC can 
be used to effectively replace or repair 
damaged cells and restore normal function 
for a whole series of diseases (see figure 
1). From infertility perspective, a long-
term objective is to create de novo patient-
 
Figure 1. The differentiation potential of human embryonic stem cells and examples of tissue specific 
diseases that are being investigated.
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specific gametes through the technology of 
therapeutic cloning for sterile patients. 
This would imply the creation of human 
somatic cell nuclear transfer embryos using 
a somatic cell of a patient (4); the 
derivation of hESC from these cloned 
embryos (5); and finally the in vitro 
differentiation of these hESC into oocytes 
or sperm. These gametes would contain the 
same genetic content as the individual 
from who the somatic cell originated to 
reconstruct the cloned embryo. 
 Although advancing rapidly, the 
field of hESC research still must overcome 
substantial challenges both fundamentally 
and clinically. Understanding the 
signalling mechanisms that underlie both 
the undifferentiated and differentiated stem 
cell state is a fist hurdle.  Large scale gene 
expression profiles failed so far to reveal 
unique factors that control self-renewal in 
hESC (6, 7). Comparative analysis has 
further provided evidence for similarities 
and differences between hESC lines in 
self-renewal, and spontaneous and directed 
differentiation. These differences may be 
associated with inherited variation in the 
sex, stage, quality and genetic background 
of embryos used for hESC line derivation, 
and/or changes acquired during passaging 
in culture and the used culture conditions 
(5, 8). There is a general consensus that 
gene expression in hESC lines is strongly 
affected by the used culture methodology 
(8). One major challenge of hESC research 
thus remains to identify factors that will 
enable researchers to propagate and 
differentiate pure populations of 
embryonic stem cells under defined 
conditions in vitro (9). 
 A whole plethora of culture 
conditions is currently being used for the 
derivation and culture of hESC which can 
influence the genetic, epigenetic and 
transcription profiles when comparing 
lines cultured or derived in different 
conditions. Hence, a uniform chemical 
defined culture environment is highly 
warranted. The increasing possibility of 
using hESC-derived cells for future clinical 
applications requires their derivation and 
maintenance to be clinically-grade and safe 
for the patient. In this context, xeno- and 
feeder-free derivation and culture of hESC 
has become a major topic of research (10). 
Small molecules targeting differentiation 
pathways are nowadays more and more 
used to replace animal-derived components 
to maintain the undifferentiated state of 
embryonic stem cells (11).  
 For clinical applications, it is a 
prerequisite that the transplanted cells are 
chromosomally normal and do not provoke 
tumour formation. Prolonged in vitro 
culture of hESC has been shown to 
generate genetic instability in hESC, 
typical for the process of „culture-
adaptation‟ (12). Also epigenetic changes 
have been demonstrated, although more 
haphazardly and independently from the in 
vitro-culture time (13). Research is being 
conducted to avoid immune-rejection or 
tumorigenicity following hESC 
transplantation and to effectively 
differentiate hESC into functional cell 
types (14, 15). A combination of HLA 
matching of the hESC lines and 
immunosuppressive medication is most 
probably the most efficient way. When 
undifferentiated hESC are transplanted in 
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vivo, they generate large tumours called 
teratomas which consist of benign masses 
of cells of differentiated tissue, but they 
can also give rise to teratocarcinomas 
containing malignant cells. Strategies are 
being investigated to eliminate this risk. 
These collaborative efforts are now 
beginning to pay off, with the first clinical 
trials using hESC to treat spinal cord injury 
and macular degeneration ongoing (16).  
 Another major challenge is 
revealing the true nature of existing hESC. 
Recently published studies have provided 
evidence that inner cell mass (ICM) cells 
undergo significant changes during the 
outgrowth phase of mouse ESC derivation 
(17). A single-cell gene expression 
analysis, performed using cells from 
whole-mouse embryos plated in 
conventional embryonic stem cell culture 
conditions, has shown that the molecular 
profile of a subgroup of cells changes 
dramatically as they progress from ICM to 
ESC status (18). These data are limited, 
and due to the lack of data on gene 
expression during crucial phases of 
immediate post-implantation development 
in humans, it remains unclear precisely 
which embryonic cell is the in vivo 
counterpart of hESC. This will also help us 
to better understand the origin of hESC, 
because recent findings suggest that all 
existing hESC lines might be of epiblast 
origin and thus not from ICM (19). The 
different states of pluripotency in mouse 
that have been found in mouse will help to 




PRODUCTION OF HUMAN 
EMBRYONIC STEM CELLS 
 
 Originally, stem cells were 
classified according to their origin or their 
in vitro or in vivo differentiation potential. 
Based on their origin, we can distinct 
embryonic, foetal and adult stem cells. 
Next to these, scientists have discovered in 
2006 a method in which somatic cells can 
be reprogrammed to an embryonic-like 
state (22).  These so-called induced 
pluripotent stem cells (iPSC) are of 
particular interest as they can provide 
autologous cells for therapeutic 
applications (23).  Although this 
breakthrough may eventually provide an 
alternative to the use of hESC, 
comparisons between iPSC and hESC are 
revealing differences that could impede 
their clinical use (23). Of particular 
concern, iPSC may exhibit gene expression 
profiles associated with cancer and 
increased levels of cancer-associated 
microRNAs (24). There are also questions 
regarding the biological equivalent of iPSC 
compared to hESC regarding their 
epigenetic state and developmental 
potential (25).  
 Based on their ability to 
differentiate into other cell types, stem 
cells are classified as being (i) totipotent: 
able to differentiate into all embryonic and 
extra-embryonic cells, (ii) pluripotent: able 
to differentiate into all cells derived from 
three germ layers, (iii) multipotent: able to 
differentiate into a limited number of cell 
fates, mostly those of a related family of 
cells and (iv) unipotent: produce only one 
cell type or tissue. In this review, only 
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human embryonic stem cells will be 
further discussed which are considered 
pluripotent.  
 Three fundamental steps are 
involved in the process of hESC derivation 
– 1) embryo and inner cell mass (ICM) 
culture, 2) initial hESC outgrowth and 
identification and 3) hESC maintenance, 
characterisation and propagation. Donated 
embryos originally created for infertility 
treatment are primarily used for hESC 
derivation. There are two main categories 
of donated embryos from which hESC 
lines arise (26). Patients can donate their 
cryopreserved embryos if they no longer 
wish to use them for fulfilling their child-
wish. These embryos are cryopreserved at 
any stage of development and are of good 
quality as they were originally intended for 
clinical treatment. The second major 
source of embryos used for hESC 
derivation comprises fresh spare embryos 
containing poor quality traits. These 
inferior quality embryos do not meet 
clinical criteria of embryo transfer or 
cryopreservation and can be donated for 
research rather than being discarded. For 
efficient hESC derivation, embryos are 
mostly cultured until the blastocyst stage, 
although hESC lines have been derived 
from earlier stages onwards including 
isolated blastomeres (27-31). Still the 
highest efficiency can be obtained from the 
blastocyst stage (32), which contains two 
distinct cell types: (i) the trophectoderm 
(TE) giving rise to extra-embryonic tissues 
such as the placenta and chorion; and (ii) 
the inner cell mass (ICM) ultimately giving 
rise to the foetus. The ICM cells are also 
the source of the pluripotent embryonic 
stem cells. Immunosurgery is frequently 
used to isolate the ICM, but also partial or 
whole blastocysts can be plated for stem 
cell derivation. For the latter, the blastocyst 
typically attaches to the substrate, flattens, 
and the TE cells grow and spread radially 
during the first several days of culture. 
Areas of ICM organization can 
subsequently be excised from the 
surrounding TE and cultured on a new 
substrate following whole blastocyst 
plating (5). Several substrates can be used 
to support hESC derivation, the most 
popular being inactivated mouse 
embryonic fibroblasts (MEFs) as a feeder 
layer (see further). The time interval 
between ICM plating and first stem cell 
outgrowth is rarely reported on (33). In 
nine published reports, the time of initial 
outgrowth from the ICM ranged from 4 to 
19 days, with the majority of hESC-like 
cells emerging between 7 and 11 days (34-
39). Morphologically, individual hESC can 
be identified by their high nucleus to 
cytoplasm ratio and prominent nucleoli. 
The initial dense colony arising from the 
plated ICM should be mechanically 
dissected into uniform clumps with a sharp 
needle and further cultured on fresh MEFs 
(40). For maintenance, rapidly self-
renewing hESC colonies require a specific 
culture environment (see further) and 
frequent passaging into smaller colonies of 
around 50 to 1000 cells to allow for 
unhindered growth (41) by mechanical or 
enzymatic means such as collagenase IV, 
dispase, or trypsin (42). Aggressive 
enzymatic passaging, however, has been 
linked to hESC lines acquiring genetic 
abnormalities (43, 44). 
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Figure 2. A summary of the steps involved in hESC derivation process at Department for Reproductive 
Medicine, Ghent University Hospital. 
 
It has to be noted that hESC generally do 
not survive well following complete 
dissociation into single cells and this may 
allow for the selection of chromosomally 
abnormal cells (41). The standard culture 
medium for hESC consist of KO-DMEM 
supplemented with a variety of factors, 
basic fibroblast growth factor (bFGF) 
being the most important one and 
refreshment of culture media is advised on 
alternating days (5). Once novel hESC 
colonies have been established, the new 
line can be propagated indefinitely and 
cryopreserved. It is essential that thorough 
characterisation of the new hESC lines is 
carried out (see next section). 
 
CHARACTERISATION OF HUMAN 
EMBRYONIC STEM CELLS 
 
 Established hESC lines are 
evaluated by a set of surface and 
transcription markers to prove their 
undifferentiated self-renewal state and by 
tests to evaluate their differentiation 
potential. Commonly used reliable markers 
that are typical for the undifferentiated 
status, include the glycolipid antigens 
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SSEA3 and SSEA4, TRA-1-60, TRA-1-81, 
protein antigens CD9, Thy1, and the class 
1 HLA antigens (45). Alternatively, cell 
surface markers can also detect the loss of 
self-renewal to assess the culture health 
such as SSEA-1, A2B5, CD56, GD2, and 
GD3 which should not be expressed in 
undifferentiated hESC (46). Next to these 
surface markers, gene expression profiling 
aids in the characterisation of the 
undifferentiated pluripotent state of hESC. 
Previous research showed that a core set of 
transcription factors (TFs), such as Oct4, 
Nanog, Sox2 and Klf4 are essential for the 
maintenance of self-renewal and 
pluripotency in embryonic stem cells in 
both mice and human (9). These factors 
function together in a regulatory loop to 
maintain pluripotency and self-renewal by 
upregulation of genes involved in key 
signalling pathways and downregulating 
genes involved in other developmental 
processes (47) and thus are considered as a 
„stemness fingerprint‟. In addition to the 
core transcription factors mentioned, genes 
that are regulated by NANOG can also be 
used as consistent hESC markers. These 
genes include GDF3, GABRB3, EBAF, 
PODXL, NODAL, ZFP42, LIN28, 
EOMES, and SFRP2 (48). Not 
surprisingly, there are many genes 
commonly expressed by hESC and human 
embryonic carcinoma cells including Oct4, 
DNMT3B, Sox2 and FoxD3 (49). Gene 
expression detection by (q)RT-PCR and 
commercially available microarray kits are 
becoming common techniques used for 
detailed hESC characterization. 
 It is highly important to determine 
the normal euploid karyotype of all newly 
derived hESC lines and to reassess their 
genetic stability during prolonged in vitro 
culture, which is subject to chromosomal 
instability (50). Especially changes in 
chromosomes 12 and 17 are detected, 
which is a hallmark of many tumours (51). 
By these aberrant chromosomal 
constitutions, hESC can easily propagate 
towards cancer-like or embryonic 
carcinoma cells (52). Karyotyping is 
typically performed by classical G-banding 
or spectral karyotyping to assess whole 
chromosomal complement. Brimble et al. 
(53) demonstrated that enzymatically 
passaged hESC (more disintegrated in 
single cells) acquired chromosomal 
abnormalities more frequently than 
mechanically passaged hESC. If hESC 
lines are to be used therapeutically, more 
sensitive techniques such as array 
comparative genomic hybridization (CGH) 
and single nucleotide polymorphism (SNP) 
array may be necessary to detect genomic 
stability at a higher resolution (54). Apart 
from this genetic stability, evaluation of 
the epigenetic stability of hESC lines has 
gained increased interest. The 5'-promoter 
regions of many transcriptional genes 
clusters of the dinucleotide CpG, which are 
methylated at transcriptionally silent genes 
and demethylated upon transcriptional 
activation. In differentiated cells, the Oct4, 
Nanog and Sox2 promoter regions are 
silent and methylated, whereas in hESC 
these promoters are active and 
unmethylated. 
 Finally, the differentiation potential 
of newly established hESC lines needs to 
prove their most defining feature, 
pluripotency. Chimera formation and 
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tetraploid-embryo complementation are the 
most stringent assays for testing 
developmental potential of mESC but are 
evidently not possible with hESC. 
Therefore in vitro embryoid formation with 
coincident histological analysis and 
teratoma formation after injection into 
immuno-deficient mice are currently the 
only two methods available to test the 
pluripotency of hESC (45). Following 
teratoma and embryoid body formation, 
immunocytochemical analysis and gene 
expression profiling indicative for cells of 
the three germ layers is carried out. It has 
to be noted that embryonic stem cells from 
non-human primates have failed to 
contribute to chimeric offspring thus far 
after blastocyst injection (55). So the full 
differentiation capacity of hESC has not 
been determined yet. Whether this is due to 
the different pluripotent states that have 




INVOLVED IN EMBRYONIC STEM 
CELL SELF-RENEWAL 
 
 Some signalling pathways have 
been shown essential to keep hESC in their 
undifferentiated state, which are different 
from mESC, and mostly agonizing and 
antagonizing each other. For hESC, the 
TGF-β /Activin/Nodal, Wnt and FGF 
pathways are the core signalling pathways 
to maintain self-renewal (56). The TGF-β 
superfamily contains the TGF-β proteins, 
activin and nodal, growth differentiation 
factors (GDFs) and BMPs, all of which are 
involved in maintaining the stem-cell state 
(9). Several studies have reported that 
activin or nodal can synergize with several 
other signalling proteins, more specifically 
FGF2 or WNTs, to promote stem-cell 
maintenance. One study even showed that 
activin supplementation alone elicits FGF2 
production which directly supports self-
renewal (57). However, the bulk of the 
evidence suggests that both activin and 
FGF2-mediated signalling pathways need 
to be activated for hESC maintenance. 
They activate the transcription factors 
SMAD2 and/or SMAD3, leading to 
downstream expression of the key 
pluripotency transcription factor Nanog in 
human ESC (9). Basic FGF was the first 
factor found to be crucial for hESC 
maintenance and is nowadays always 
incorporated in the derivation and culture 
medium. HESC express receptors for 
FGFs, thereby producing FGF2 and 
activating signalling through ERK1 and 
ERK2 in these cells (58). The precise 
interaction of these FGF2-mediated and 
MEK-ERK mediated signalling and the 
network of pluripotency transcription 
factors is still unknown (9). Similarly, the 
exact role of the Wnt pathway remains 
uncertain as it could have only a 
proliferative function (59, 60). 
 In contrast, the first key element for 
maintaining self-renewal in mESC was the 
leukaemia inhibitory factor (LIF). LIF is 
activating the pro-self-renewal pathway 
JAK/STAT3 (signal transducer and 
activator of transcription 3) pathway, 
which is functioning through regulation of 
c-Myc, Klf4, Klf5, Oct4, Sox2 and Nanog; 
and the pro-differentiation MAPK pathway 
(61). The action of LIF signalling requires 
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the presence of serum, which can be 
replaced by BMPs which -induces the 
expression of Id (inhibitor of 
differentiation) proteins and attenuates the 
activity of the pro-differentiation MAPK-
responsive transcription factors (62). 
Importantly, mouse ESC can also be 
maintained in a combination of small 
molecule inhibitors that block the MAP-
kinase signalling pathway which normally 
leads to differentiation (63, see further). 
Thus, the combined actions of LIF and 
BMPs selectively promote mESC 
maintenance in their undifferentiated 
status. Intriguingly, small molecules that 
inhibit or activate all these signalling 
pathways have become a useful tool to 
manipulate cell fate (see next sections). 
 
CHALLENGES IN HESC RESEARCH 
 
EFFICIENCY OF HESC DERIVATION 
 
 The International Stem Cell 
Registry now has documented more than 
thousand novel hESC lines derived in 
laboratories worldwide. Unfortunately, 
discrepancies in the reporting of hESC 
derivation methodology make it difficult to 
assess its efficiency. It is almost impossible 
to ascertain from the literature a true 
efficiency for deriving a hESC line from 
embryos. The number of used embryos is 
not always revealed or presented in an 
inconclusive way. Furthermore, the quality 
of the used embryos or blastocysts is rarely 
described. It has to be noted that the larger 
the experience of a group in embryology 
and/or cell culture, the higher the success 
rates of hESC derivation will be (64; own 
experience). Still, the chances of success of 
producing human ESC lines largely depend 
on whether blastocyst formation can first 
be achieved and the quality of used 
blastocysts (32). The reported efficiency of 
hESC derivation from fresh poor quality 
embryos that develop into blastocysts 
ranges from 4.1 to 25% (5). In comparison, 
using frozen-thawed good quality embryos, 
the hESC derivation efficiency ranges from 
13 to 50 % between identical replicates 
(65). Given the lack of pre-implantation 
embryo scoring details, it long was 
uncertain whether the quality of used 
embryos would influence hESC derivation 
success rates. Recording of the number of 
embryos allocated to research and 
developing to blastocysts and subsequent 
stem cell derivation would also give 
important feedback to the IVF lab 
regarding their culture system and success 
rates (33). Ström et al. (66) concluded that 
there was no influence of embryo 
morphology when fresh embryos were 
classified as good versus poor quality 
embryos on the establishment of hESC 
lines. Still, the individual traits or scores of 
embryos were not correlated directly to 
hESC derivation efficiency. More 
information on the latter was recently 
reported by O‟Leary et al. (5). They 
showed that although embryos with 
different poor quality traits (fragmentation 
level, multinucleation, delayed 
development, abnormally fertilised 
embryos) were all able to make blastocysts 
with good-quality ICMs, the ICMs were 
unequal in their ability to derive hESC. 
Good-quality ICMs from embryos with 
two or more poor quality traits were unable 
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to generate hESC lines, in contrast to 
good-quality ICMs originating from 
embryos with a single poor-quality trait 
(5). These results suggest that when 
experiments aiming at hESC derivation are 
designed, a proper randomisation of the 
embryos allocated to different 
experimental groups is warranted. Other 
publications suggested the possible 
influence of the cohort of embryos within a 
patient on derivation success (65, 67, 68). 
In one study, the efficiency of hESC 
derivation in five patients was 66.6% (18 
hESC lines from 27 blastocysts) in contrast 
to the study‟s overall efficiency of 32.1% 
(65). Apart from embryo cohort influence, 
this implies also that patient characteristics 
might influence hESC derivation success. 
It is well known that patient-specific 
parameters such as maternal age and 
responsiveness to ovarian stimulation can 
also impact embryo development and 
competency in IVF (69, 70). Indeed it was 
shown recently that embryos originating 
from older patients or from cycles that did 
not result in pregnancy had significantly 
diminished blastocyst development and 
ICM quality (71). Interestingly, embryos 
originating from women older than 37 
years were not able to support successful 
hESC derivation, which corresponds to the 
poor prognosis of pregnancy success with 
increasing age in assisted reproductive 
technology. HESC generating cohorts had 
the highest blastocyst formation rates, 
which contained the highest percentage of 
good-quality ICM and had the highest 
pregnancy rate, indicative for an overall 
increase in cohort health (71). So, from 
these studies it can be concluded that 
embryo traits, cohort and patient 
parameters of the embryos used for hESC 
derivation attempts will affect the success 
rate and thus can influence outcome 
parameters. 
 To date, no studies have been 
reported to increase the derivation 
efficiency of hESC except for one. Fan et 
al. (72) showed that a modified embryo 
culture medium supplemented with both 
recombinant human LIF and bFGF 
significantly increased blastocyst 
formation rates which resulted in a seven-
fold increase in derivation efficiency. 
Given the control group was performed 
one year prior to the experimental group 
and improper randomisation of the 
embryos was performed, results from that 
study could be biased.  The original 
protocol by which the first mESC were 
successfully established was only efficient 
for a very limited number of mouse strains 
(especially the 129 mouse strain) and was 
not widely transferable to other species. In 
this “permissive” mouse strain, 
LIF/STAT3 signalling was sufficient to 
obtain pluripotent stem cells (73, 74). 
These findings proved that distinct 
pluripotent states can be specified by 
culture conditions but also that the genetic 
background determines the requirements 
for exogenous factors to obtain the 
pluripotent stem cells. In 2008, the 
signalling pathways that regulate the naive 
state of mouse ESC pluripotency became 
clearer (63). Hence, it was determined that 
small molecule inhibition of GSK3 
signalling by Chir99021 and FGF-MAPK 
signalling by PD0325901 in the presence 
of LIF could maintain mESC in defined, 
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feeder-free conditions (63). This new 
culture system, known as „2i+LIF‟, also 
allowed the efficient derivation of naïve 
ESC from any non-permissive mouse 
strains tested as well as from the rat (75).  
Subsequently, a combination of three 
factors (LIF and 2 small molecules: 
PD98059 and BIO) was shown to yield a 
fivefold higher mouse ES cell derivation 
rate compared with that of LIF alone (76). 
More recently, the combination of the Rho 
kinase inhibitor Y-27632 preventing 
apoptosis and accutase significantly 
increased the derivation rate in the 
C57BL/6×129/Sv mouse strain (77). So it 
seems that supplementing derivation 
conditions with appropriate external 
signalling can significantly increase 
derivation efficiency. This has not been 
proven yet in hESC derivation attempts. 
 
CHEMICAL DEFINED CONDITIONS 
FOR HESC CULTURE 
 
 Although the derivation and culture 
of hESC has progressed enormously since 
the first publication over a decade ago (1), 
currently used procedures are usually still 
ill-defined, differ substantially from each 
other and mostly contain animal derived 
products rendering them unsuitable for 
possible future regenerative cell therapies 
(78). Clinical applications of hESC based 
cell-therapies require their derivation and 
maintenance to be clinically-grade and safe 
for the patient, as defined by both the 
European Medicines Agency and the Food 
and Drug Administration. All sources of 
animal- or human-derived contamination 
should be eliminated. Stable long-term 
maintenance of self-renewing and 
pluripotent hESC traditionally involved the 
use of feeder cells, mostly mouse 
embryonic fibroblasts (MEFs). The culture 
medium necessary for the cultivation of 
hESC contains various animal proteins and 
additional exogenous factors. These 
undefined culture conditions present many 
problems. In particular, the use of serum 
products (with batch-to-batch variation) 
can compromise the consistency of the 
hESC culture, and complicate comparative 
biological studies between different hESC 
lines.  
 Several groups have attempted to 
exclude individual animal components by 
using feeder-free matrices (79, 80) feeder 
cells of human origin (35, 81-83), or 
defined xeno-free media (80). Crook et al. 
claimed to have created the first six hESC 
lines suitable for therapeutic use but 
animal derived components such as serum 
replacement were still used and the 
established lines were not maintained for a 
long period (84). One year earlier, Ludwig 
et al. already reported the derivation of 
hESC lines in „defined conditions‟ but 
these lines were shown to be 
karyotypically unstable after prolonged 
passaging (80). Recently, Ilic et al. 
reported the derivation and culture of five 
hESC lines under clinical-grade conditions, 
one of which was presented to the UK 
Stem Cell Bank for further evaluation with 
the goal to make the cell line available to 
other researchers (85).  
 Another more fundamental 
approach aiming towards more chemically 
defined conditions has focused on the 
signalling pathways involved in self-
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renewal and pluripotency. Small 
molecules, targeting specific signalling 
pathways and/or mechanisms, have been 
shown to be useful chemical tools in 
manipulating cell fate, state and function, 
and are playing increasingly important 
roles in elucidating the fundamental 
biology of stem cells (11). For example, 
after screening of 50 000 small molecules 
in the absence of feeder layers, serum and 
LIF, pluripotin (SC-1) was identified as a 
potent and specific small molecule 
supporting mESC expansion in the 
undifferentiated state (86). Burton et al. 
(87) succeeded in the maintenance of 
hESC in the absence of both feeders and 
cytokines by using the compound erythro-
9-(2-hydroxy-3-nonyl)adenine (EHNA). 
Recently, Tsutsui et al. (88) reported a 
“golden combination” of small molecules 
(a MEK inhibitor, GSK3 inhibitor and 
ROCK inhibitor) enabling maintenance of 
hESC on a fibronectin-coated surface by 
single cell passaging. It has to be taken into 
account that all these studies have started 
from existing hESC already exposed to 
animal-derived components during 
derivation and initial culture. All these 
combined efforts should soon lead to the 
derivation of hESC in chemically defined 
conditions which would be more suitable 
for future clinical cell-based therapies 
using cells derived from hESC. 
 
(EPI-)GENETIC STABILITY OF HESC 
AND TUMOUR FORMATION 
 
 Maintaining a hESC line by weekly 
mechanical passaging is time, money and 
effort consuming. But it has been proven to 
be the safest and most reliable method for 
the long term propagation of hESC, as the 
development of genetic abnormalities 
during culture has not been reported (89). 
Bulk culture of hESC normally involves 
enzymatically passaging of hESC which 
leads to a dramatic expansion of hESC. 
However, it coincides with an increase in 
genetic instability, methylation changes 
and mitochondrial mutations, similarly 
observed in cancer and Embryo Carcinoma 
(EC) cells (43, 53). EC cells are the 
transformed unstable counterparts of 
hESC, which display very similar 
cytogenetic abnormalities to hESC with 
acquired genetic abnormalities such as 
trisomy 12, 17 and X (43, 53). Even 
subkaryotypic changes and point mutations 
in coding regions might arise in stem cell 
cultures (90) which demand more accurate 
and expensive methods for the evaluation 
of the genomic integrity, such as array 
comparative genomic hybridization and 
single-nucleotide polymorphism array 
(SNP array). Recently, SNP arrays showed 
that structural variants occur sporadically 
in a large study including 125 hESC lines 
(12). Next to genetic errors that may occur 
during in vitro culture, it has been shown 
that hESC undergo a range of epigenetic 
modifications upon prolonged culture in 
serum free culture conditions, including 
dramatic changes in methylation. Holm et 
al. found that loss of methylation in ESC is 
directly related to tumorigenesis (91). Loss 
of imprinting leads to a higher growth rate, 
a shortened cell cycle time, cellular 
immortality, resistance to TGFβ, and foci 
formation on a confluent monolayer. 
Evaluation of some imprinted genes 
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revealed some abnormal epigenetic states 
and expression of for example IGF2 and 
H19 in some hESC lines (92). It is clear 
that a deeper understanding of the 
molecular mechanisms that control the 
genetic stability of hESC is required and 
culture methods that prevent genetic 
instability will need to be optimized, since 
large amounts of undifferentiated stem 
cells of high quality are needed for future 
regenerative medicine approaches.  
 Apart from the genetic stability 
within the hESC culture, a major concern 
with future hESC-based cell therapy is that 
of tumorigenic potential. Therefore, it is 
imperative to assess the heterogeneity of a 
culture, as the engraftment of 
undifferentiated or incorrectly 
differentiated cells may present a 
substantial tumorigenic risk to the recipient 
(93). In this respect, a particular difficulty 
is the ability to monitor cell distribution 
after transplantation to distinct them from 
host cells. This is especially relevant when 
the cells are administered intravenously, 
rather than locally, since broad 
dissemination is likely to occur. It is not 
yet possible to quantify the tumour risk 
associated with the introduction of hESC-
derived cells in vivo. This risk will be 
ameliorated by developing appropriate 
purification protocols and the means for 
monitoring contamination. Transgenic 
methods are being investigated to modify 
hESC lines in such way that only 
differentiated cells survive after 
engraftment as has recently been proposed 
in iPSC-based therapies (94), although 
such genetic modification could also alter 
the cell characteristics.  
DIFFERENT STATES OF STEM CELL 
PLURIPOTENCY 
 
 Despite their same ICM origin, 
hESC are clearly dissimilar from their 
mESC counterparts. Since all stages of 
embryogenesis in mice are experimentally 
accessible, different types of stem cells 
with distinct characteristics have been 
derived which suggested that the 
differences between mouse and human 
probably correspond to different stages of 
embryonic development from which they 
originate (20). Pluripotent stem cells were 
derived from the epiblast of the post-
implantation mouse embryo in growth 
conditions similar to hESC, giving rise to 
the so called epiblast stem cells (EpiSC) 
(95, 96). As such, pluripotent cell types 
were classified into two fundamentally 
distinct states of pluripotency (21, 97): (i) 
„the naive state‟ = the inner cell mass-like 
pluripotent state, which is typical for 
mESC derived from the pre-implantation 
ICM and (ii) „the primed state‟ = epiblast-
like state, characteristic for mouse EpiSC 
isolated from the post-implantation 
embryos. Naive ESC can be cloned with 
high efficiency as packed dome colonies, 
efficiently contribute to chimeras, maintain 
both X chromosomes in an active state 
(XaXa), and are relatively refractory in 
their potential for primordial germ cell 
differentiation (9). In contrast, primed stem 
cells are characterized by a flattened 
morphology, show intolerance to single 
cell passaging, are highly inefficient in 
chimera contribution, have undergone X-
chromosome inactivation (XiXa), and are 
poised for differentiation into primordial 
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germ cell precursors. Importantly, the 
signalling pathways/external signals for 
unlimited self renewal are also different 
and mostly antagonizing each other (9, 21): 
the growth of primed stem cells depends 
on signalling by Activin, FGF2, ERK1/2, 
and TGF-ß while BMP4 and LIF/STAT3 
signalling stabilizes naive ESC. 
Given the shared morphology, culture 
requirements and signalling pathways, it 
has been suggested that existing hESC are 
more similar to mouse EpiSC (9). Little is 
known about the temporal changes that 
occur as the ICM progresses to the stem 
cell outgrowth state or the importance of 
timing for these events. A single-cell gene 
expression analysis in mice had shown that 
the molecular profile of a subgroup of cells 
changes dramatically as they progress from 
ICM to ESC status (18). The cellular 
organization and molecular changes that 
occur during the transition from human 
ICM to hESC were recently demonstrated 
(19). It was shown for the first time that 
the human ICM in culture developed first 
to an epiblast-like structure before the 
generation of pluripotent hESC. This 
structure, which was termed the post inner 
cell mass intermediate (PICMI), was found 
to be an essential intermediate in all of the 
hESC derivations (19). The PICMI 
possessed a unique molecular signature 
and combined characteristics of early and 
late mouse epiblast and even showed some 
primordial germ cell markers. The PICMI 
was shown to be a closer progenitor of 
hESC than the ICM and its existence, 
together with the observed dynamics of 
hESC derivation, had further elucidated the 
origin of hESC (19). This was the first 
proof that all existing human ESC 
contained a primed state of pluripotency 
(98). Importantly, primed mouse EpiSC 
cells do not contribute (or very poorly) to 
chimera formation which is one of the 
most stringent tests of differentiation 
capacity. In contrast, naive mESC 
contribute very efficiently to chimeras (9). 
As the existing hESC are thought to be 
primed, it is very likely that the 
differentiation potential is also limited 
which has consequences for regenerative 
purposes (21). Interestingly, in response to 
external signals, the two different 
pluripotent stem cell types show high 
plasticity and can be converted to each 
other.  
 
CLINICAL APPLICATIONS USING 
HESC 
 
 Despite much progress and accrued 
knowledge at the basic science research 
level, the clinical use of hESC is still in its 
infancy. This lag in application of hESC 
from its isolation over 10 years ago is 
largely due to concerns of tumour 
formation (see above), as well as ethical 
and related legal issues. Still, the lack of 
detailed characterisation of most 
established hESC lines causes a major 
concern for manufacturers and end-users 
since an enormous investment is necessary 
when taking a cell line through to a 
medicinal product. A minimum 
characterisation is required to deposit a 
clinical grade line which should include 
passage number before submission, DNA 
fingerprinting, karyotype, viral and sterility 
testing, viability and functional 
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differentiation assays and expression of 
pluripotent markers (33).  The application 
of hESC based cell therapies has been 
proposed for a whole series of diseases, 
mostly aging-associated diseases (99). The 
latter has become a primary focus in the 
biomedical field since the number of 
individuals aged 65 years and older is 
expected to dramatically increase within 
the near future due to the baby boom 
generation between 1945 and 1964.  
 Current hESC research is very 
much focussed on the optimisation of in 
vitro differentiation protocols to enrich 
pure, homogeneous populations of specific 
functional cell types belonging to the three 
germ layers that can be used for 
transplantation. The differentiation of 
hESC towards mesoderm derivates such as 
cardiomyocytes has attracted great interest 
(100). The high prevalence of heart 
disease, along with the scarcity of hearts 
and heart tissues available for 
transplantation and the associated clinical 
and autoimmune problems of 
transplantation, make this line of research 
imperative. HESC are known to 
differentiate to myocytes morphologically 
similar to cardiomyocytes which display 
normal cardiomyocyte function and 
electrophysiological properties by 
culturing in a specific condition medium or 
treatment with bone morphogenetic 
protein-4 (BMP-4) and activin A (100). 
Until now, clinical trials of hESC have not 
been started for cardiac diseases, but the 
successful application in repairing heart 
failure in the mouse system has 
encouraged scientists to develop such 
therapy for human patients.  
 Endodermal derivatives from hESC 
include cells that populate the lung, liver, 
pancreas, urinary bladder, pharynx, 
thyroid, parathyroid, and digestive system 
(99). Type 1 diabetes for example is a 
disease in which a specific type of cell, 
insulin-producing pancreatic beta cells, is 
damaged or destroyed by the patient‟s own 
immune system. Although the strategy of 
treating diabetes with beta cell 
transplantation is clinically possible, it is 
also very much limited by the shortage of 
donors. Therefore, the generation of 
insulin-secreting cells from hESC has 
gained much interest. Unfortunately, 
similar to hepatocytes differentiation, in 
vitro beta cell differentiation from hESC is 
very hard and inefficient. By using a step-
wise in vitro differentiation protocol, some 
progress has been achieved recently (101). 
In a similar manner, a highly robust 
population of functional hepatocytes was 
proven possible (102). Still, differentiation 
of endodermal cell types from established 
hESC remains inefficient. The successful 
derivation of a new state of naive 
pluripotent hESC might alleviate this 
problem. 
 Interestingly, the dominant 
differentiation pathway in hESC cultures 
leads to the formation of ectoderm 
derivates including cells of the nervous 
system and the epidermis (99). One of the 
most exciting and most advanced possible 
therapeutic applications of hESC is for 
patients who have been paralyzed by 
catastrophic spinal cord damage. A USA 
Biotech company Geron began Phase I 
safety trials of its technique for converting 
stem cells into a type of neuronal cell, 
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known as oligodendrocyte progenitor cells, 
intended for injection into the patient‟s 
spinal cord at the site of injury. The 
intention, which has been repeatedly 
demonstrated in animal tests, was that the 
newly-injected oligodendrocytes might 
repair the damaged insulation around the 
severed nerve cells of the spinal cord, and 
thereby enable those cells to once again 
send signals to the patient‟s limbs and 
organs. Due to internal re-organisation 
within the company, this clinical trial has 
unfortunately recently been halted (103). 
Therapies using hESC-derived cells on 
neurodegenerative diseases such as 
Parkinson‟s disease, Alzheimer‟s disease, 
and Amyotrophic Lateral Sclerosis (ALS) 
are also under investigation by the 
generation of functional neurons. For 
example, hESC-differentiated 
dopaminergic (DA) neurons that can 
secrete dopamine were produced for the 
treatment of Parkinson's disease and found 
to have therapeutic effect in animal models 
(99). Retinal pigment epithelium cells are 
another specific cell type derived from 
neuroectoderm that are of interest for 
hESC based cell therapy. Two clinical 
trials testing retinal cells derived from 
hESC (for age-related macular 
degeneration and Stargardt‟s macular 
dystrophy) have recently reported positive 
preliminary results as there were visual 
improvements in the patients (103). No 
signs of tumor or other abnormal growths, 
retinal detachments, or immune rejection 
of the hESC-derived cells were noticed, 
but the final results are only expected in 
2013. It has to be noted that these 
preclinical and clinical hESC based trial 
phases has largely been funded by private 
corporations without government support.  
HESC have also been implicated as 
potential cell-based therapy for cancer 
treatment. Recent studies have 
demonstrated that hESC can differentiate 
into NK cells which produced cytokines 
and performed antibody-mediated 
cytotoxicity on targeted cells (104). In 
perspective of infertility treatment, hESC 
have been differentiated towards sperm 
and oocyte precursor cells, but functional 
gametes were not obtained yet. In mice, 
functional sperm was successfully obtained 
from naive mESC (105) which reinforces 
the need for creation of naive hESC which 
differentiation potential towards gametes 




 For possible clinical applications of 
hESC derived cells, there are still many 
scientific challenges that must be 
addressed. The field of regenerative 
medicine is relatively young and it would 
be wrong to overpromise on the speed and 
scope of such research to patients and their 
families. Firstly, we need to define the real 
pluripotent state of existing hESC given 
the significant overlap with mouse EpiSC. 
Is it possible to derive naive hESC or does 
this state of pluripotency not exists in 
human? What are the differentiation 
capacities of naive hESC compared to their 
primed counterparts? These are 
fundamental questions that should be first 
answered before any clinical application 
should be considered. We also need to 
make sure that the hESC derived cells 
P Belg Roy Acad Med Vol. 1: 89-111  B. Heindryckx et al. 
___________________________________________________________________________ 
106 
behave in predictable ways and do not 
produce tumours. Thorough 
characterisation of established hESC lines 
using state-of-the-art molecular techniques 
is a very important first step in this. 
Finally, we need to figure out how to get 
human embryonic stem cells to 
differentiate down specific pathways in a 
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